Investors: Stock Information
Exchange and ticker
Allarity Therapeutics is listed on Nasdaq First North Growth Market Sweden as ALLR.
Share capital
As per 11 November, 2020, the Company’s share capital is 9,937,244 of nominal DKK 0.05 each, and the number of shares are 198,744,880 DKK.
Share capital is set in Danish kroner (DKK). All shares give equal rights to the company’s assets, profits and any possibly liquidation surplus.
Identification code (ISIN)
The company is listed on NASDAQ OMX Nasdaq First North Growth Market, ISIN code (identification code for the company’s shares) is ISIN DK0060732477.
Share price
Shareholders
Shareholder details
As of 11 November 2020, the company had 7,205 shareholders.
As of 11 November 2020, the shareholder base were as follows:
| Shareholder name | Number of shares | Percentage |
|---|---|---|
| Sass & Larsen | 36,860,251 | 18.6 % |
| UBS Switzerland AG | 11,667,050 | 5.9 % |
| Others | 150,217,579 | 75.5 % |
| Total | 198.744.880 | 100 % |
Investor warrants
Investor warrants series TO 2
The investor warrants of series “Allarity Therapeutics TO 2″ is traded on Nasdaq First North Growth Market under the ticker “ALLR TO 2“.
The total number of warrants within the series is 50,341,080.
Terms and conditions
One (1) investor warrant received when participating in the rights issue in Oncology Venture (now Allarity Therapeutics) at the end of 2019 gives the right to subscribe for one (1) new share in Oncology Venture A/S (now Allarity Therapeutics) at an issue price of 6.00 SEK.
Investors in the Rights Issue will have the possibility to exercise their warrants in five two-week windows during the 24-months period during which the warrants may be exercised.
These periods are:
- April 1, 2020 – April 15, 2020
- September 1, 2020 – September 15, 2020
- February 1, 2021 – February 15, 2021
- May 1, 2021 – May 15, 2021
- September 1, 2021 – September 15, 2021
